Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alphaTIGIT-guided IL-15 mimetic
- Development stage
- Preclinical
- Lead developer
- Hefei TG ImmunoPharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The alphaTIGIT-guided IL-15 mimetic is an engineered bispecific antibody-based cytokine agonist designed to overcome the systemic toxicity and structural instability associated with native IL-15. Developed using AlphaFold3-assisted structural modeling, this molecule combines an IL-15 mimetic with a TIGIT-targeting domain. This 'cis-targeting' strategy ensures that the cytokine activity is precisely directed toward TIGIT-expressing immune cells, specifically activating and expanding intratumoral CD8+ stem-like T cells. In preclinical models, this approach has demonstrated potent antitumor activity and a favorable safety profile compared to non-targeted IL-15 mimetics, which often show limited in vivo efficacy. The construct aims to bridge the gap between immune checkpoint blockade and cytokine therapy by providing targeted immune stimulation within the tumor microenvironment.
- Other names
- αTIGIT-guided IL-15 mimeticTIGIT-targeted IL-15 mimetic
02
Targets
IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on alphaTIGIT-guided IL-15 mimetic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alphaTIGIT-guided IL-15 mimetic.